Rexulti
REXULTI / RXULTI was discovered by Otsuka and is being co-developed and co-marketed, where approved, by Otsuka and Lundbeck for the treatment of schizophrenia. In the U.S. it is also co-marketed as an adjunctive treatment for major depressive disorder. In 2018 it was launched in Japan, and is now sold in approximately 60 countries worldwide. It acts as an SDAM(serotonin-dopamine activity modulator).
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling
